Clinical trials: Survival , Tumor
Esophageal Squamous Cell Carcinoma
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
This purpose of this observational study is to review medical chart and patient survey data collection within an early access to medicines scheme (EAMS) program.
- Trial name
- NCT04936399
- Testing
- Nivolumab
- Where
- 36 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
This parallel, randomized, open-label, multi-centre study will evaluate the effect on overall survival of trastuzumab (Herceptin) in combination with a chemotherapy compared to the chemotherapy alone in patients with…
- Trial name
- NCT01041404
- Testing
- Trastuzumab, Fluorouracil, Cisplatin
- Where
- 142 sites in Australia, Belgium and 22 more
- Volunteers
- 584 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
The purpose of this study is to determine if the True Human Monoclonal antibody Xilonix (MABp1) can prolong the life of colorectal carcinoma patients that are refractory to standard therapy.
- Trial name
- XCITE (NCT01767857)
- Testing
- Xilonix
- Where
- 113 sites in United States, Australia and 11 more
- Volunteers
- 643 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Melanoma, Unresectable Melanoma
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated…
- Trial name
- NCT05155254
- Testing
- IO102-IO103, Pembrolizumab
- Where
- 112 sites in United States, Australia and 14 more
- Volunteers
- 407 people
- Sponsor
- IO Biotech
Colorectal Cancer
An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)
This single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously…
- Trial name
- NCT01277120
- Where
- Romania
- Volunteers
- 174 people
- Sponsor
- Hoffmann-La Roche
Prostate Cancer
A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617
The aim of this study was to evaluate patient characteristics, treatment patterns, prostate-specific antigen (PSA) reduction, and overall survival (OS) of prostate cancer patients treated with 177-Lutetium-Prostate-Specific…
- Trial name
- NCT07450157
- Where
- United States
- Volunteers
- 6,448 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms, Castration-Resistant
Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
This observational prospective single arm cohort study is designed to assess overall survival, symptomatic skeletal event free survival and quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients…
- Trial name
- URANIS (NCT02450812)
- Testing
- Radium-223-dichloride (Xofigo, BAY88-8223)
- Where
- Germany
- Volunteers
- 86 people
- Sponsor
- Bayer
Thrombosis, Venous
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).
- Trial name
- NCT00312013
- Testing
- Nadroparin
- Where
- 95 sites in Belgium, Canada and 9 more
- Volunteers
- 503 people
- Sponsor
- GlaxoSmithKline
Renal Cell Cancer
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in participants with metastatic renal cell cancer (clear cell type) who have had nephrectomy.
- Trial name
- NCT00738530
- Testing
- Bevacizumab [Avastin], Interferon alfa 2a [Roferon]
- Where
- 104 sites in Australia, Belgium and 16 more
- Volunteers
- 649 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
This 2 arm study will compare the efficacy and safety of Avastin plus Herceptin/docetaxel, versus Herceptin/docetaxel alone, in patients with HER2 positive locally recurrent or metastatic breast cancer who have not received prior…
- Trial name
- NCT00391092
- Testing
- bevacizumab [Avastin], Docetaxel, Herceptin
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 424 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
In the China extension study, Chinese participants with programmed cell death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) will be randomized to receive single agent pembrolizumab for up to 35 treatments or…
- Trial name
- NCT03850444
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Volunteers
- 262 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
The purpose of this study is to examine the efficacy and safety as well as the characteristics of the female hormone and study medications after administration in pre-menopausal women with estrogen receptor positive advanced…
- Trial name
- NCT01073865
- Testing
- ZD9393 (Zoladex) 10.8 mg, ZD9393 (Zoladex) 3.6 mg
- Where
- 55 sites in India, Japan and 4 more
- Volunteers
- 222 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate…
- Trial name
- PSMAddition (NCT04720157)
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Where
- 164 sites in United States, Austria and 17 more
- Volunteers
- 1,144 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Prostate Cancer
A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer
The purpose of the protocol is to assess the rate of castration resistance, disease progression and overall survival over a 3-year period post-androgen deprivation therapy (ADT) induction in a study cohort of patients with…
- Trial name
- TRIPTOCARE LT (NCT01383863)
- Where
- 35 sites in Denmark, France and 5 more
- Volunteers
- 180 people
- Sponsor
- Ipsen
Small Cell Lung Cancer
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
The purpose of this study is to evaluate whether increasing or maintaining hemoglobin concentrations with darbepoetin alfa, when administered with platinum-containing chemotherapy in subjects with previously untreated…
- Trial name
- NCT00119613
- Testing
- darbepoetin alfa
- Volunteers
- 600 people
- Sponsor
- Amgen
Multiple Myeloma Survival Outcome, Multiple Myeloma and Malignant Plasma Cell Neoplasms
Multiple Myeloma Extramedulary Disease Samples FFPE
This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with extramedullary multiple myeloma, together with their…
- Trial name
- MMExFFPE (NCT07354555)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- BIWAKO
Breast Cancer
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
This 2 arm study will compare the efficacy and safety of continuation or discontinuation of Herceptin treatment in combination with 2nd line chemotherapy, in patients with HER2 positive metastatic breast cancer whose condition…
- Trial name
- NCT00448279
- Testing
- trastuzumab, Chemotherapy
- Where
- 35 sites in Italy
- Volunteers
- 58 people
- Sponsor
- Hoffmann-La Roche
Prostatic Neoplasms
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic…
- Trial name
- PSMAfore (NCT04689828)
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Where
- 72 sites in United States, Austria and 12 more
- Volunteers
- 469 people
- Sponsor
- Novartis Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
CemiplimAb Survivorship Epidemiology
The objectives of the study are: To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced (defined as locally advanced or metastatic [nodal or distant]) cutaneous…
- Trial name
- CASE (NCT03836105)
- Testing
- cemiplimab
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 287 people
- Sponsor
- Regeneron Pharmaceuticals
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
- Trial name
- MACS1295 (NCT01129336)
- Testing
- Zoledronic acid, Standard Therapy
- Where
- 33 sites in United States
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals